Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (INVIGORATE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04209205
Recruitment Status : Completed
First Posted : December 24, 2019
Last Update Posted : July 20, 2022
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : May 17, 2022
Actual Study Completion Date : May 17, 2022